Hologic (NASDAQ:HOLX) Receives Overweight Rating from Stephens

Stephens reaffirmed their overweight rating on shares of Hologic (NASDAQ:HOLX) in a research report released on Thursday,Benzinga reports. Stephens currently has a $78.00 price target on the medical equipment provider’s stock.

Other equities research analysts have also issued research reports about the stock. Mizuho set a $75.00 target price on shares of Hologic in a report on Thursday, July 31st. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. Evercore ISI boosted their target price on Hologic from $62.00 to $68.00 and gave the stock an “in-line” rating in a report on Tuesday, July 8th. Argus raised Hologic from a “hold” rating to a “buy” rating and set a $80.00 price target for the company in a report on Monday, August 18th. Finally, Morgan Stanley boosted their price objective on Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $78.62.

Hologic Stock Performance

NASDAQ:HOLX opened at $68.27 on Thursday. Hologic has a 12-month low of $51.90 and a 12-month high of $84.39. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $15.18 billion, a PE ratio of 28.33, a price-to-earnings-growth ratio of 2.47 and a beta of 0.57. The firm has a 50-day moving average price of $66.46 and a 200 day moving average price of $62.72.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the previous year, the business earned $1.06 earnings per share. The company’s quarterly revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts anticipate that Hologic will post 4.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC grew its holdings in Hologic by 22.3% during the 1st quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider’s stock worth $113,000 after acquiring an additional 335 shares during the period. United Services Automobile Association bought a new stake in Hologic in the first quarter valued at approximately $347,000. SG Americas Securities LLC raised its holdings in Hologic by 116.6% in the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider’s stock worth $594,000 after purchasing an additional 5,172 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of Hologic during the first quarter worth $641,000. Finally, Cambridge Investment Research Advisors Inc. increased its position in shares of Hologic by 1.7% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider’s stock valued at $1,980,000 after buying an additional 528 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.